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Vascular dysfunction in obese 
diabetic db/db mice involves the 
interplay between aldosterone/
mineralocorticoid receptor and Rho 
kinase signaling
Aurelie Nguyen Dinh Cat1, Glaucia E. Callera2, Malou Friederich-Persson1,3, Ana Sanchez  4, 
Maria Gabriela Dulak-Lis1, Sofia Tsiropoulou1, Augusto C. Montezano1, Ying He2, Ana M. Briones5, 
Frederic Jaisser6 & Rhian M. Touyz  1,2
Activation of aldosterone/mineralocorticoid receptors (MR) has been implicated in vascular dysfunction 
of diabetes. Underlying mechanisms are elusive. Therefore, we investigated the role of Rho kinase 
(ROCK) in aldosterone/MR signaling and vascular dysfunction in a model of diabetes. Diabetic obese 
mice (db/db) and control counterparts (db/+) were treated with MR antagonist (MRA, potassium 
canrenoate, 30 mg/kg/day, 4 weeks) or ROCK inhibitor, fasudil (30 mg/kg/day, 3 weeks). Plasma 
aldosterone was increased in db/db versus db/+. This was associated with enhanced vascular MR 
signaling. Norepinephrine (NE)-induced contraction was increased in arteries from db/db mice. 
These responses were attenuated in mice treated with canrenoate or fasudil. Db/db mice displayed 
hypertrophic remodeling and increased arterial stiffness, improved by MR blockade. Vascular calcium 
sensitivity was similar between depolarized arteries from db/+ and db/db. Vascular hypercontractility in 
db/db mice was associated with increased myosin light chain phosphorylation and reduced expression 
of PKG-1α. Vascular RhoA/ROCK signaling and expression of pro-inflammatory and pro-fibrotic markers 
were exaggerated in db/db mice, effects that were attenuated by MRA. Fasudil, but not MRA, improved 
vascular insulin sensitivity in db/db mice, evidenced by normalization of Irs1 phosphorylation. Our data 
identify novel pathways involving MR-RhoA/ROCK-PKG-1 that underlie vascular dysfunction and injury 
in diabetic mice.
The high mortality and morbidity rates worldwide associated with obesity-related type 2 diabetes are attributed, 
in large part, to cardiovascular complications. Evidence suggests a link between hyperaldosteronism, obesity and 
hypertension, and clinical findings show a positive correlation between body weight and plasma aldosterone 
levels1,2. We and others demonstrated that aldosterone, through mineralocorticoid receptor (MR) activation, is 
involved in the regulation of structural and functional vascular changes, in particular in endothelial dysfunc-
tion and vascular hypercontractility, often associated with obesity-related type 2 diabetes and hypertension. MR 
blockade improves obesity-related vascular injuries, as well as insulin sensitivity3–7. Although plasma levels of 
aldosterone are elevated and expression of MR is increased in obesity and diabetes3,8,9 mechanisms by which 
aldosterone/MR signaling impact on vascular remodeling and function in these conditions remains unclear. 
We recently demonstrated that adipocyte MR activation influences vascular function and signaling through 
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redox-dependent mechanisms and RhoA/Rho kinase (ROCK)10. Activation of the RhoA/ROCK signaling path-
way plays an important role not only in enhanced vascular tone in hypertension11–13, but also in cellular metabolic 
processes, including insulin resistance14–18. It can be surmised therefore that the RhoA/ROCK pathway consti-
tutes a potential point of cross-talk linking metabolic and hemodynamic abnormalities with insulin resistance 
and obesity. The role of ROCK as an effector of aldosterone/MR activation in vascular injury in obesity-associated 
diabetes is unknown and was the focus of our study.
Results
Morphological features of db/db and db/+ mice. Body weight was greater in db/db mice versus db/+ 
(35.2 ± 0.6 vs 18.5 ± 0.4 g, n = 6 mice per group, p < 0.001) with no change in systolic blood pressure (data not 
shown). Fasting plasma glucose was increased in db/db versus db/+ (30.1 ± 3 vs 12.3 ± 6 mmol/ml, n = 6 mice 
per group, p < 0.01). Plasma aldosterone levels were increased in db/db compared with db/+ control mice 
(Fig. 1A). Canrenoate did not have any effect on plasma aldosterone levels (Fig. 1A). Interestingly, fasudil reduced 
non fasting plasma levels of insulin and glucose in db/db, but not in db/+ mice (Fig. 1B,C). Canrenoate treatment 
did not reduce plasma levels of insulin and glucose in db/db mice (Supplementary Fig. 1A,B).
Upregulation of aldosterone/MR signaling in arteries from db/db mice. Transcripts levels of Nr3c2 
(MR gene) (Fig. 1D) and serum and glucocorticoid regulated kinase 1 (Sgk-1), a downstream target of MR acti-
vation (Fig. 1E) were increased in mesenteric arteries from db/db compared to db/+ control mice. Canrenoate 
treatment reduced the increase in vascular Sgk1 mRNA levels (Fig. 1E), but not in vascular Nr3c2 mRNA levels 
(Fig. 1D). Although protein levels of Nr3c2 were unchanged in all groups, protein levels of the plasminogen 
Figure 1. Plasma aldosterone, insulin and glucose concentrations and Nr3c2 and Sgk1 levels in arteries from 
db/db versus db/+ mice. (A) Plasma aldosterone levels are increased in db/db. MR antagonist treatment 
has no effect. Non fasting plasma levels of insulin (B) and glucose (C) are increased in db/db vs db/+ mice, 
and fasudil reduces both in db/db, but not in db/+. Nr3c2 (D) and Sgk1 (E) mRNA levels are increased in 
mesenteric arteries from db/db vs db/+ mice. MR antagonist treatment abolished increased Sgk1, but not 
Nr3c2 mRNA levels in mesenteric arteries from db/db versus db/+ mice. Ubc was used as housekeeping gene 
for normalization. Results are expressed mean ± SEM, n = 6–8 mice per group, **p < 0.01, ***p < 0.001 db/
db vs db/+, †p < 0.05, ††p < 0.01 vehicle vs +MRA. MRA: MR antagonist (canrenoate); Nr3c2: nuclear receptor 
subfamily 3 group C member 2 (mineralocorticoid receptor); vs: versus. Vehicle: saline NaCl 0.9%; Ubc: 
ubiquitin C.
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activator inhibitor-1 (PAI-1), known to be a downstream target of vascular MR activation, were significantly 
increased in db/db vs db/+ mice. Canrenoate treatment reduced this increase (Supplementary Fig. 1C,D).
Effect of MR blockade with canrenoate on vascular structural and functional changes in db/db 
mice. Maximum responses to high concentration of potassium chloride (KCl) were identical between db/+ 
control and db/db mice (response to KCl: db/+ vs db/db, 2.0 ± 0.3 vs 1.9 ± 0.2 mN/mm; n = 6 mice per group, 
non significant (NS)). Norepinephrine (NE)-induced contraction of mesenteric arteries with intact endothe-
lium was significantly increased in db/db versus db/+ control mice (Fig. 2A), as well as in arteries in which the 
endothelium had been mechanically denuded (Supplementary Fig. 2). Chronic treatment with potassium can-
renoate (30 mg/kg/day, 4 weeks) prevented vascular hypercontractility to NE in arteries from db/db vs db/+ mice 
(Fig. 2A). The hypercontractility is not associated with changes in the active pressure which has been estimated 
with the myography data settings and was not significantly modified between groups (Supplementary Table S2).
Db/db mice displayed hypertrophic inward remodeling (Supplementary Fig. 3A–C) in small resistance arter-
ies with increased vascular wall to lumen ratio and cross sectional area (CSA) in vehicle-treated obese db/db mice 
(Fig. 2B,C). These structural changes were prevented by canrenoate treatement. Moreover, the leftward shift of the 
stress-strain relationship, shown in Fig. 2D, indicated decreased elasticity in mesenteric arteries from db/db mice, 
which was prevented by canrenoate treatment.
Rho kinase inhibitor fasudil improved vascular hypercontractility of arteries from db/db 
mice. Small GTPases of the Rho family influence vascular tone primarily by regulating smooth muscle con-
traction. Considering the significant alteration of vascular contractility in db/db mice, we explored the possibility 
that RhoA/ROCK may be involved. Db/db and db/+ mice were treated in vivo with fasudil, which decreased 
NE-induced contraction in mesenteric resistance arteries from both strains (Fig. 3A). Moreover, the relaxation 
Figure 2. Vascular remodeling and function in arteries from db/db versus db/+ mice. (A) NE-induced 
contraction of mesenteric resistance arteries from control db/+ and db/db mice, treated by an MR antagonist 
(30 mg/kg/day, 4 weeks) or vehicle (saline), was performed using a wire myograph. Increased NE-induced 
contractility in db/db mice was prevented by canrenoate treatment. Structural and mechanical parameters 
were assessed by pressurized myography in mesenteric arteries from db/db vs db/+ mice. Vascular wall to 
lumen ratio (B) and CSA (C) were increased in db/db mice. (D) The stress-strain relationship was shifted to 
the left indicating that vascular stiffness is increased in db/db vs db/+ mice. All of these vascular changes were 
prevented by canrenoate treatment. Results are expressed mean ± SEM, n = 6–8 mice/group, *p < 0.05 db/db vs 
db/+, †p < 0.05 vehicle vs +MRA. CSA: cross sectional area; MRA: MR antagonist (canrenoate). Vehicle: saline 
NaCl 0.9%.
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curve obtained with increasing doses of fasudil was significantly shifted to left (Fig. 3B), indicating that arteries 
from db/db compared to db/+ mice are more sensitive to fasudil due to an exacerbation of ROCK activity in the 
vasculature of db/db mice.
Vascular contractility regulated by ROCK is calcium-independent in db/db mice. ROCK activa-
tion is often associated with enhancement of calcium sensitivity. We hypothesized that arteries of db/db mice are 
more sensitive to calcium than arteries of db/+ controls, which may account partially for the hypercontractility 
observed in basal conditions. Calcium sensitization was assessed by stepwise increases of extracellular calcium 
concentration (0 to 5 mmol/l) in endothelium-denuded and depolarized (90 mmol/l KCl) mesenteric arteries. 
However, our results showed no alteration of the calcium sensitivity in db/db vs db/+ mice since there is no dif-
ference in contractile responses between arteries from db/db and db/+ mice in basal conditions, suggesting no 
alteration in calcium sensitivity (Supplementary Fig. 4A).
We next addressed whether ROCK contributes to vascular calcium sensitization by incubating arter-
ies with fasudil (10 μmol/l, 30 min). Fasudil decreased calcium sensitivity similarly in db/+ and db/db mice 
(Supplementary Fig. 4B), but the gap is slightly greater in arteries from db/db (db/db vs db/+: −42.9 versus 
−27.4% of KCl 90 mmol/l), suggesting that ROCK is over-activated in arteries from db/db versus db/+ mice, 
but not calcium-independent. In fasudil-treated mice, calcium-induced contraction was decreased in arteries 
from db/db but not in db/+ mice (Supplementary Fig. 4C), which is in line with our previous in vitro results with 
fasudil.
Rho kinase activity and signaling are increased in arteries from db/db mice. ROCK activity was 
significantly increased (3.4-fold) in mesenteric arteries from db/db compared to db/+ mice (Fig. 4A). This was 
associated with increased phosphorylation of downstream targets of ROCK signaling, myosin phosphatase sub-
unit 1 (Mypt1) (Fig. 4B) and myosin light chain (Mlc) (Fig. 4C). Fasudil significantly reduced the levels of Mypt1 
and Mlc phosphorylations, as expected (Supplementary Table S3). To investigate some molecular mechanisms 
involved in the increased vascular ROCK activity in db/db mice, we focused on cyclic GMP-dependent kinase G 
(PKG)-1α which negatively regulates ROCK activity. As shown in Fig. 4D, protein levels of PKG-1α were signifi-
cantly decreased in mesenteric arteries from db/db mice compared with db/+ controls.
Partial regulation of ROCK activity by MR. Chronic treatment with canrenoate partially decreased vas-
cular ROCK activity in db/db mice (Fig. 4A). The increase in Mypt1 and Mlc phosphorylation was blunted by MR 
blockade (Fig. 4B,C). In addition, canrenoate treatment significantly increased PKG-1α protein levels in arteries 
from db/db vs db/+ mice (Fig. 4D). However, vascular ROCK-1 and ROCK-2 protein lvels were unchanged in 
all groups (Supplementary Fig. 5A,B). Moreover, protein kinase C (PKC) is also a key player which when is acti-
vated contributes to vascular hypercontractility, independently to rho kinase. In arteries from db/db mice, PKC 
phosphorylation was significantly increased compared to db/+. This was partially prevented by MR blockade 
(Supplementary Fig. 5C). These results suggest that MR regulate several signalling pathways in order to control 
vascular contractility.
Fasudil improved vascular insulin signaling in arteries from db/db mice. We next questioned 
whether fasudil influences insulin signaling in db/db mice and whether this involves MR. Previous studies exam-
ined the role of ROCK in insulin resistance in obesity16–18, but those studies focused on adipose tissue. Here we 
examined vascular insulin resistance. Insulin receptor substrate 1 (Irs1) phosphorylation at serine 307 (which 
negatively controls tyrosine-phosphorylated Irs1 by insulin receptor associated with insuline resistance) was 
Figure 3. Rho kinase inhibitor fasudil improved contractility of arteries from db/db mice. (A) NE-induced 
contraction of mesenteric resistance arteries from control db/+ and db/db mice, treated by a Rho kinase 
inhibitor Fasudil (30 mg/kg/day, 3 weeks) or vehicle (saline), was performed using a wire myograph. (B) Dose-
dependent fasudil-induced relaxation curve (10−9 to 10−4 mol/l) was shifted to the left for db/db vs db/+ mice. 
Data are presented as mean ± SEM; n = 6–8 mice/group, *p < 0.05 db/db vs db/+, †p < 0.05 vehicle vs +fasudil. 
NE: norepinephrine; Vehicle: saline NaCl 0.9%.
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significantly increased in mesenteric arteries from db/db mice (Fig. 5A). Akt activation, as evaluated through 
its phosphorylation on serine 473, was decreased in mesenteric arteries from db/db compared to db/+ mice 
(Fig. 5B). These results suggest that db/db mice display vascular insulin resistance. Fasudil significantly improved 
vascular insulin signaling and restored normal levels of Irs1 and Akt phosphorylation (Fig. 5A,B). This is in line 
with the decrease in plasma levels of insulin and glucose in db/db mice treated by fasudil, but not in db/+ mice. 
We next questioned whether the beneficial effects of fasudil on vascular insulin signaling was regulated by MR. 
We examined Irs1 and Akt phosphorylations in mesenteric arteries from db/db and db/+ mice, which were 
increased in db/db vs db/+ but canrenoate treatment had no effect (Fig. 5C,D). This is supported by the fact 
that plasma levels of insulin and glucose in canrenoate-treated db/db mice remained increased (Supplementary 
Fig. 1A,B).
Effect of MR blockade on vascular levels of pro-fibrotic and pro-inflammatory markers in db/
db mice. We analysed the expression of some pro-fibrotic and pro-inflammatory markers, which may be 
responsible for vascular damage in db/db mice and assessed whether MR plays a role. Vessels from db/db mice 
Figure 4. Rho kinase activity is increased in mesenteric arteries from db/db versus db/+ mice. (A) Rho kinase 
activity was assessed by enzymatic immunoassay. Upregulation of downstream targets of Rho kinase activation 
with Mypt-1 (B) and Mlc (C) phosphorylation in db/db vs db/+ mice. (d) PKG-1α protein levels are decreased 
in mesenteric arteries from db/db vs db/+ mice. These changes were prevented by canrenoate treatment. Results 
are expressed as mean ± SEM, n = 6–8 mice per group, *p < 0.05, **p < 0.01 db/db vs db/+, †p < 0.05 vehicle vs 
+MRA. Vehicle: saline NaCl 0.9%.
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exhibited increased expression of Col1a (3-fold), Col3a (2.5-fold) and Tgfβ1 (2.2-fold) compared to db/+ mice. 
These changes were partially reduced by canrenoate treatment (Fig. 6A). In addition, we evaluated mRNA levels 
of pro-inflammatory markers Il-6, Tnfα and Mcp-1. Gene expression of these pro-inflammatory markers was 
increased in db/db mice, effects that were attenuated by MRA (Fig. 6B).
Discussion
Type 2 diabetes, a major risk factor for cardiovascular disease, is characterised by endothelial dysfunction and 
vascular remodeling, phenomena observed in experimental models and patients with diabetes. Exact mecha-
nisms underlying these processes remain elusive, although oxidative stress, activation of the renin angiotensin 
system, advanced glycation end products (AGEs)/receptor for AGEs (RAGE) and hyperglycaemia have been 
implicated. We previously demonstrated an important role for aldosterone/MR in vascular damage and met-
abolic derangement in obesity-associated diabetes5–7,10 and others have shown a role for ROCK in endothelial 
Figure 5. Fasudil improved vascular insulin signaling in db/db versus db/+ mice, and this is MR-independent 
pathway. Fasudil treatment prevents increased Ser-307-phosphorylation of Irs1 (A) and decreased Ser-473 
phosphorylation of Akt (B) in mesenteric arteries from db/db vs db/+ mice. However, canrenoate treatment has 
no effect on the increase in Irs1 phosphorylation (C) neither on the decrease in Akt phosphorylation (D) in db/
db mice. Data are presented as mean ± SEM; n = 6 to 8 mice/group. *p < 0.05, **p < 0.01 db/db vs db/+. Irs1: 
Insulin receptor substrate 1; MRA: MR antagonist canrenoate. Vehicle: saline NaCl 0.9%. Results are expressed 
mean ± SEM, n = 6–8 mice per group, *p < 0.05, **p < 0.01 db/db vs db/+, †p < 0.05, ††p < 0.01 vehicle vs 
+fasudil. Irs1: insulin receptor substrate 1; Vehicle: saline NaCl 0.9%.
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dysfunction in cerebral arteries in diabetes19. Here we questioned the relationship between aldosterone/MR, 
ROCK and vascular dysfunction in a mouse model of type 2 diabetes. Major findings demonstrate that in db/
db mice, which are obese and have hyperaldosteronism and vascular MR hyperactivation: (i) hypercontractil-
ity is reduced by canrenoate and fasudil, (ii) upregulation of vascular RhoA/ROCK pro-contractile signaling is 
ameliorated by ROCK inhibition and MR blockade and is related to decreased cGMP-dependent PKG-1 activity, 
(iii) increased vascular expression of pro-inflammatory and pro-fibrotic mediators are downregulated by canre-
onate, and (iv) ROCK contributes to insulin resistance through MR-independent mechanisms. Taken together 
our data suggest that hyperaldosteronism and MR hyperactivation in db/db mice are associated with vascular 
dysfunction and arterial remodeling through ROCK and PKG-1α signaling, which influences pro-contractile, 
pro-inflammatory and pro-fibrotic pathways. The downstream vascular signaling through the interplay between 
MR and ROCK is not a generalised phenomena, because insulin resistance appears to be ROCK-dependent and 
MR-independent. Our findings define a novel pathway through MR-ROCK in diabetes-associated vasculopathy, 
as summarised in Fig. 7.
It is generally accepted that obesity and diabetes are associated with an increased risk of hypertension, heart 
failure and atherosclerosis, but the mechanisms involved are still not fully understood. Adipose tissue is an endo-
crine organ with multiple metabolic roles in regulating whole-body physiology. Moreover, the fat surrounding the 
blood vessels, PVAT, plays a functional role in regulating the contractile state of the underlying smooth muscle 
cell layer by releasing vasoactive factors that diffuse into the vascular wall and modulates vascular tone20–24. In 
obesity and diabetes, PVAT is dysfunctional and induces vascular dysfunction, contributing to the development 
of cardiovascular disorders in these metabolic diseases25–28. We previously showed that PVAT influences vascular 
function and signaling through MR-dependent signaling pathways in obesity-associated diabetes4,5,10. Here, we 
performed our studies in the absence of PVAT and focused on MR-dependent signaling involved in vasoconstric-
tion, vascular stiffness, fibrosis and inflammation. We highlight the critical role played by MR activation in these 
processes since canrenoate treatment normalised contractility and reduced vascular injurious events, including 
inflammation and fibrosis, in db/db mice. These vascular effects are independent of PVAT-derived factors.
We explored the potential role of RhoA/Rho kinase activation, a major signaling pathway regulating vascular 
smooth muscle contraction, to explain the hypercontractile phenotype and the vascular resistance observed in 
diabetic mice. Vascular insulin resistance is considered as an early contributor to vascular damage. The contractile 
state of vascular smooth muscle is driven by phosphorylation of the regulatory protein, MLC and reflects the bal-
ance of the Ca2+-calmodulin-dependent myosin light chain kinase and myosin light chain phosphatase (MLCP) 
activities29. Phosphorylation of Mypt1 at Thr-696 plays a dominant role in MLCP inhibition and has been shown 
to be increased in vasoconstriction-associated with hypertension12,13. Our molecular studies showed that ROCK 
activity and its downstream signaling (Mypt-1 and Mlc phosphorylations) are increased in arteries from db/db 
compared to db/+. Fasudil and canrenoate treatments restored vascular function in db/db mice, suggesting a 
role for MR upregulation and over-activation of ROCK/Mypt-1/Mlc signaling in hypercontractility in diabe-
tes. MR blockade only partially decreased ROCK activity, suggesting that other mechanisms are also involved 
Figure 6. Pro-fibrotic and pro-inflammatory markers mRNA levels in arteries from db/db and db/+ mice. 
(A) Pro-fibrotic markers such as Col1a, Col3a and Tgfb1 mRNA levels were increased in mesenteric arteries 
from db/db compared to db/+ mice. (B) Pro-inflammatory markers such as IL-6, Tnfa and Mcp-1 mRNA 
levels were increased in mesenteric arteries from db/db compared to db/+ mice. Ubc was used as housekeeping 
gene for normalization. Results are expressed mean ± SEM, n = 6–8 mice per group, *p < 0.05, **p < 0.01 db/
db vs db/+, †p < 0.05 vehicle vs +MRA. Vehicle: saline NaCl 0.9%. IL-6: interleukine-6; Mcp-1: monocyte 
chemoattractant protein 1; Tnfα: tumor necrosis factor alpha; Tgfβ1: transforming growth factor beta 1; Ubc: 
ubiquitin C.
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in MR-sensitive vascular dysfunction in diabetes, such as PKC activation and Ca2+-calcineurin pathways30–33. 
Indeed, our results showed that activation of PKC in db/db mice is also regulated by MR.
ROCK inhibition, but not MR blockade, improved insulin signaling by decreasing Irs1 phosphorylation at 
serine-307 and by increasing Akt phosphorylation. Serine-307 phosphorylation of Irs1 has been shown to mediate 
insulin resistance34–36. The fact that insulin sensitivity was unaffected by canrenoate, but was improved by fasudil indi-
cates that vascular insulin resistance in db/db mice is ROCK-dependent and MR-independent. These results are differ-
ent from other studies where MR blockade improved glucose tolerance and reduced insulin resistance in obesity37–40. 
However those studies were performed in experimental models of diet-induced obesity, whereas we examined obese 
db/db mice. Our findings unravel a novel ROCK mechanism underlying vascular insulin resistance in diabetic mice 
and highlighted the interest in analyzing the effects of combination treatment MRA with fasudil. We previously showed 
that MR over-activation in adipocytes (Adipo-MROE mice) leads to weight gain, insulin resistance and dyslipidaemia 
but also increased H2O2 levels associated with hypocontractility through activation of PKG-1α10.
In summary, our study demonstrates an important role for aldosterone/MR upregulation and ROCK hyperac-
tivation in endothelium-dependent and -independent vascular hypercontractility and dysfunction in db/db mice. 
The interplay between MR and ROCK influences pro-contractile, pro-inflammatory and pro-fibrotic molecular 
processes that underlie diabetes-associated vascular changes. These phenomena are highly regulated because insu-
lin resistance is ROCK-dependent and MR-independent. Our novel findings emphasize the functional impor-
tance of MR and ROCK activation in cardiovascular complications associated with obesity and diabetes. While 
canrenoate and fasudil, when given separately, ameliorated vascular damage in db/db, some responses were only 
partial. Combining MR blockers with ROCK inhibitors may have additive vasoprotective effects that might reduce 
cardiovascular complications in diabetes as reported by a clinical study demonstrating that eplerenone decreased 
the enhanced ROCK activity in circulating leukocytes in hypertensive patients41. Such a notion, which awaits further 
confirmation, may have therapeutic potential especially in patients with diabetes and high cardiovascular risk.
Material and Methods
The study was approved by the Animal Ethics Committee of the University of Ottawa. All studies in animals 
were conducted in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory 
Animals. All procedures were in accordance with institutional guidelines.
Animal model. Male, 8 week-old, db/db mice [B6.BKS(D)-Lepr <db>/J], a model of type 2 diabetes mel-
litus, and age-matched heterozygote non-diabetic mice [(db/+)], were purchased from Jackson Laboratories 
(Maine, USA). Mice were maintained in the animal facility under controlled temperature (22–24 °C) and humid-
ity, 12-hour light/dark cycles, fed with standard diet and water ad libitum.
Figure 7. Hypothetical scheme of putative signaling mechanisms induced by aldosterone/MR over-activation 
in obesity. On one hand, aldosterone/MR induces ROCK activity through decreased PKG-1a, resulting in 
vascular hypercontractility of arteries from obese db/db mice. In obesity-related diabetes, ROCK may also 
contribute to vascular insulin resistance independently of MR. In addition, vascular remodeling, due to 
increased pro-fibrotic and pro-inflammatory signaling, is also regulated, in part, by MR. MLC: myosin light 
chain; Mypt1: myosin light chain phosphatase subunit 1; MR: mineralocorticoid receptor; PKG-1α: cGMP-
dependent protein kinase G type 1 isoform alpha; ROCK: Rho kinase; p: phosphorylated.
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Mice were treated with vehicle (saline), MR antagonist (MRA), potassium canrenoate for 4 weeks (30 mg/
kg body weight/day) or Rho kinase inhibitor, fasudil (30 mg/kg body weight/day) for 3 weeks, by daily subcu-
taneous injections. At the end of the treatment, animals were euthanized by cervical dislocation and blood and 
tissues were collected. Mesenteric resistance arteries were used to assess vascular reactivity by wire myography 
and structural and mechanical properties by pressure myography. Biochemical and molecular biology studies 
were performed in plasma and vascular tissue.
Vascular studies. Second order branches of mesenteric arteries without perivascular fat (PVAT) were iso-
lated from db/db and db/+ control mice and mounted on a wire myograph (DMT myograph, ADInstruments 
Ltd, Oxford, UK) as previously described10. Arteries were equilibrated for 20 min in physiological salt solution 
(in mmol/l: 120 NaCl, 25 NaHCO3, 4.7 KCl, 1.18 KH2PO4, 1.18 MgSO4, 2.5 CaCl2, 0.026 EDTA, and 5.5 glucose), 
continuously bubbled with 95% O2 and 5% CO2 to achieve a pH of 7.4 at 37 °C. Maximal responses with high 
potassium solution (120 mmol/l KCl) and 10−5 mol/l of norepinephrine (NE) were performed in order to verify 
functional integrity of the arteries. Contraction curves to cumulative increasing doses of NE (10−9 to 10−5 mol/l) 
were performed in arteries with and without (mechanically removed) intact endothelium. Dose-response curves 
for fasudil-induced relaxation (10−9 to 10−4 mol/l) were also obtained in arteries pre-contracted with NE at a 
concentration to achieve approximately 80% of maximal response.
Structural and mechanical parameters were evaluated with a pressure myograph (Living Systems, Burlington, 
Vermont). Briefly, the vessel was secured on two glass microcannulae, set to 70 mmHg and equilibrated (60 min, 
37 °C) in oxygenated calcium-free Krebs–Henseleit solution (pH = 7.3–7.4; 0Ca-KHS, mmol/l: 119 NaCl, 4.7 KCl, 
24 NaHCO3, 1.18 KH2PO4, 1.2 MgSO4 and 10 EGTA). The vessels were set to an internal pressure of 10 mmHg 
and a pressure–diameter curve was then obtained by increasing intraluminal pressure in 20 mmHg steps (from 
10 to 120 mmHg), with internal and external diameters (Di0Ca and De0Ca, respectively) being measured. Vascular 
structural and mechanical parameters were calculated as previously described10.
Calcium sensitization was assessed by stepwise increases of extracellular calcium concentration (0 to 
5 mmol/l) in endothelium-denuded and depolarized (90 mmol/l KCl) mesenteric arteries.
Enzymatic immunoassays. Aldosterone levels measurement. Blood samples were collected into hepa-
rinized tubes, centrifuged at 2000 g at 4 °C for 15 min and plasma was further stored at −80 °C until analysis. 
Aldosterone concentrations were determined in plasma from db/db and db/+ control mice by enzyme immuno-
assay (EIA) (#10004377, Cayman Chemical, Ann Arbor, MI, USA) according to the manufacturer’s instructions.
Insulin and glucose levels determination. Non fasting insulin and glucose plasma levels were determined in db/
db and db/+ control mice by ELISA kit (#EZRMI-13K, Merck Millipore, Fontenay sous bois, France) accord-
ing to the manufacturer’s instructions and glucose GOD-POD kit (#981780, Thermo Fischer Scientific, Illkirch, 
France) optimized for Konelab analyzer (Konelab 20i, Thermo Fisher Scientific).
Rho Kinase Activity. Enzymatic activity of Rho kinase was evaluated using a Rho-associated Protein Kinase 
Activity Assay Kit (Merck Millipore #CSA001, East Midlands, United Kingdom) and the experiments were per-
formed in mesenteric arteries and aortic protein lysates, according to the manufacturer’s instructions.
Western blot analysis. Mesenteric arteries of db/+ and db/db mice were lysed for western blotting with 
buffer containing: 50 mmol/l Tris, pH 7.4; 5 mmol/l EGTA, 2.5 mmol/l EDTA, 1 mmol/l Na2VO3, 1 mmol/L 
PMSF, 1 µg/ml pepstatin A, 1 µg/ml leupeptin, and 1 µg/ml aprotinin and 0.5% Triton x-100. 30 μg of protein 
were separated by electrophoresis on a 10% SDS-polyacrylamide gel and transferred onto a nitrocellulose mem-
brane (Bio-Rad, Hertfordshire, United Kingdom). Nonspecific binding sites were blocked with 5% skim milk 
in Tris-buffered saline solution with 0.1% Tween-20 for 1 hour at 24 °C. Membranes were then incubated with 
specific antibodies overnight at 4 °C. Antibodies were as follows: anti-Phospho-Akt (Ser-473) (1:1000, #9271, 
Cell Signalling Technology, Danvers, MA, USA), anti-Akt (1:1000, #9272), anti-Phospho-Irs1 (Ser-307) (1:1000, 
#2381, Cell Signalling Technology), anti-Irs1 (1:1000, #2382), anti-Phospho-Mypt1 (Thr-696) (1:1000, #sc-17556, 
Santa Cruz Biotechnology, CA, USA), anti-Mypt1 (H-130) (1:1000, #sc-25618), anti-Phospho-Mlc (Thr18/Ser19) 
(1:1000, #3674, Cell Signalling Technology), anti-Mlc (1:1000, #3672), anti-plasminogen activator inhibitor-1 
(PAI-1) (1:1000, sc-6642, Santa Cruz Biotechnology), anti-phospho PKCβ/δ (Ser-660/Ser-662) (1:1000, 
sc-365463, Santa Cruz Biotechnology), anti-PKC (1:1000, sc-80, Santa Cruz Biotechnology), anti-PKG-1 (1:1000, 
3248, Cell Signalling Technology), anti-Rock1 (1:1000, sc-17794, Santa Cruz Biotechnology) and anti-Rock-2 
(1:1000, sc-398519, Santa Cruz Biotechnology). The Nr3c2 antibody (MR, 5D1, 1:500) was kindly provided by Pr 
C. Gomez-Sanchez. Membranes were incubated with horseradish peroxidase-conjugated secondary antibodies 
for 1 hour at room temperature. Thereafter signals were detected by chemiluminescence and visualised by auto-
radiography. The same membrane was used to determine β-actin expression as an internal housekeeping control 
using a mouse monoclonal antibody (1:10 000, Sigma Chemical Co, St Louis, MO, USA). Blots were analyzed 
densitometrically using the ImageJ software.
Quantitative real time Polymerase Chain Reaction. Total RNA was extracted from mesenteric 
arteries as previously described5. Real time PCR was carried out on a 7900HT Fast Real-Time PCR machine 
with 384-Well Block Module (Applied Biosystems, Thermo Fischer Scientific, Paisley, United Kingdom) using 
gene-specific primers to quantify the relative abundance of each gene with SYBR Green I as the fluorescent mol-
ecule. The primers used were designed using the software Primer 3 and are listed in Electronic Supplemental 
Material Methods (Supplementary Table S1). PCR was performed in duplicate for each sample using a PCR 
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Master mix for SYBR Green I (Applied Biosystems) containing 300 nmol/l primers, and 3 µl template cDNA in 
10 µl total volume. PCR conditions consisted of an activation step of the Taq DNA polymerase (95 °C) for 10 min, 
followed by 40 cycles of 10 s at 95 °C (denaturation step) and 1 min at 60 °C (primer annealing, extension, and 
fluorescence acquisition). Serial dilution of pooled cDNA was used in each experiment to assess PCR efficiency. 
Ubiquitin C (Ubc) housekeeping gene was used as the reference gene for normalization. The relative copies num-
ber of the target genes were calculated with the 2(−ΔΔCt) method, after assessment that PCR efficiency was 100%.
Drugs and solutions. NE and potassium canrenoate were obtained from Sigma-Aldrich Ltd (Dorset, United 
Kingdom). Fasudil was obtained from Tocris (Cederlane Corp., Burlington, ON, Canada). NE was dissolved in 
distilled water. Fasudil was dissolved in dimethylsulfoxide. Potassium canrenoate was dissolved in sodium chlo-
ride NaCl 0.9% (saline).
Data analysis. Values reported are means ± SEM. Differences between groups were assessed with the non-
parametric Mann-Whitney test. Western blot and real time PCR data were statistically analysed with one-way 
ANOVA, followed by Bonferroni multiple comparison test. Vascular reactivity results were assessed with 
two-ways ANOVA with repeated measures, followed by Bonferroni multiple comparison test, as appropriate. 
Values of p < 0.05 were considered significant.
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